A5075968422- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Pharmacogenetics and Drug Metabolism
- Antibiotic Use and Resistance
- Genetic Associations and Epidemiology
- Pharmaceutical Practices and Patient Outcomes
- Renin-Angiotensin System Studies
- Antibiotic Resistance in Bacteria
- Eicosanoids and Hypertension Pharmacology
- Atrial Fibrillation Management and Outcomes
- Metabolomics and Mass Spectrometry Studies
- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical studies and practices
- Bacterial Identification and Susceptibility Testing
- Pneumonia and Respiratory Infections
- Cardiac electrophysiology and arrhythmias
- Receptor Mechanisms and Signaling
- Cardiac Arrhythmias and Treatments
- Venous Thromboembolism Diagnosis and Management
- Heart Rate Variability and Autonomic Control
- Diet and metabolism studies
- Sodium Intake and Health
- Antimicrobial Resistance in Staphylococcus
- Pharmacology and Obesity Treatment
- Diabetes Treatment and Management
University of Florida
2014-2024
Florida College
2011-2022
Columbus Oncology and Hematology Associates
2019
The University of Texas Health Science Center at Houston
2009-2018
University of Chicago
2016-2018
Mayo Clinic in Florida
2016-2018
Baylor College of Medicine
2018
The Ohio State University
2018
Pacific University Oregon
2018
Ain Shams University
2018
Metoprolol is a selective β-1 adrenergic receptor blocker that undergoes extensive metabolism by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). Our objective was to investigate influence of CYP2D6 polymorphisms on efficacy and tolerability metoprolol tartrate. Two hundred eighty-one participants with uncomplicated hypertension received 50 mg twice daily followed response-guided titration 100 daily. Phenotypes were assigned based results genotyping copy number variation assays. Clinical...
To identify novel genes influencing blood pressure response to thiazide diuretic therapy for hypertension, we conducted genome-wide association meta-analyses of ≈1.1 million single-nucleotide polymorphisms in a combined sample 424 European Americans with primary hypertension treated hydrochlorothiazide from the Pharmacogenomic Evaluation Antihypertensive Responses study (n=228) and Genetic Epidemiology (n=196). Polymorphisms associated at P<10(-5) were tested replication associations...
The primary objective of this study was to determine if a pharmacist‐managed anticoagulation monitoring service (AMS) improved the outcomes patients receiving warfarin in family practice setting and cost effective treating preventing thromboembolic disorders. A retrospective chart review performed on all at University Florida's Family Practice Residency Program who received pharmacotherapy between October 1, 1988, December 15, 1993. followed by AMS were compared with those control group...
Age and race categories or renin profiling have been recommended to predict blood pressure responses monotherapy with a beta-blocker thiazide diuretic. Whether these other characteristics when the drugs are administered as add-on therapy is uncertain.We evaluated predictors of response in 363 men women < =65 years age primary hypertension (152 blacks, 211 whites), 86 whom (24%) were untreated 277 (76%) withdrawn from previous antihypertensive before randomization either atenolol followed by...
Background Identification of genetic markers antihypertensive drug responses could assist in individualization hypertension treatment. Methods and Results We conducted a genome‐wide association study to identify gene loci influencing the responsiveness 228 male patients 4 classes drugs. The Genetics Drug Responsiveness Essential Hypertension ( GENRES ) is double‐blind, placebo‐controlled cross‐over where each subject received amlodipine, bisoprolol, hydrochlorothiazide, losartan, as...
Single-nucleotide polymorphisms (SNPs) in NEDD4L may influence the ability of protein to reduce epithelial sodium channel expression. A variant NEDD4L, rs4149601, was associated with antihypertensive response and cardiovascular outcomes during treatment thiazide diuretics β-blockers a Swedish population. We sought further evaluate associations between polymorphisms, blood pressure β-blockers.Four SNPs, rs292449, rs1008899 rs75982813, were genotyped 767 patients from Pharmacogenomic...
Our aim was to identify financial and outcome benefits of therapeutic intervention by a multidisciplinary antimicrobial treatment team composed pharmacists, clinical microbiologist, an infectious disease specialist. Of 252 consecutive inpatients receiving suboptimal intravenous antibiotics identified the pharmacist, 127 were prospectively randomized 125 control group. The groups similar with regard severity illness, infection type, time from admission randomization. Physicians received...
We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with without abdominal obesity using data from a randomized, open-label study evidence cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg 100 monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, uric acid levels were measured at baseline after combination therapy. Outcomes new...
G protein-coupled receptor kinases (GRKs) are important regulatory proteins for many receptors, but little is known about GRK4 pharmacogenetics. We hypothesized that 3 nonsynonymous single-nucleotide polymorphisms, R65L (rs2960306), A142V (rs1024323), and A486V (rs1801058), would be associated with blood pressure response to atenolol, not hydrochlorothiazide, long-term cardiovascular outcomes (all-cause death, nonfatal myocardial infarction, stroke) in participants treated an atenolol-based...
To date, 39 single nucleotide polymorphisms (SNPs) have been associated with blood pressure (BP) or hypertension in genome-wide association studies whites. Our hypothesis is that the loci/SNPs BP/hypertension are also BP response to antihypertensive drugs.We assessed of these loci atenolol hydrochlorothiazide monotherapy 768 hypertensive participants Pharmacogenomics Responses Antihypertensive study. Linear regression analysis was performed on whites for each SNP an additive model adjusting...
The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the gene (ADRBK1) determined if these a Gln41Leu polymorphism affect blood pressure (BP) response to atenolol or hydrochlorothiazide adverse cardiovascular outcomes hypertensives.ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs tested mRNA expression differences 96 lymphoblastoid cell line...
The aim of this study is to identify single-nucleotide polymorphisms (SNPs) influencing blood pressure (BP) response the β-blocker atenolol.Genome-wide association analysis BP atenolol monotherapy was performed in 233 white participants with uncomplicated hypertension pharmacogenomic evaluation antihypertensive responses study. Forty-two P less than 10 for either diastolic or systolic were validated four independent groups hypertensive individuals (total n = 2114).In whites, two near gene...
Pharmacogenetic testing (PGT) is increasingly being used as a tool to guide clinical decisions. This article describes the development of an outpatient, pharmacist-led, pharmacogenetics consult clinic within internal medicine, its workflow, and early results, along with successes challenges. A pharmacogenetics-trained pharmacist encouraged primary care physicians (PCPs) refer patients who were experiencing side effects/ineffectiveness from certain antidepressants, opioids, and/or proton pump...
Resistant hypertension (RHTN), defined by lack of blood pressure (BP) control despite treatment with at least 3 antihypertensive drugs, increases cardiovascular risk compared controlled hypertension. Yet, there are few data on genetic variants associated RHTN.We used a gene-centric array containing ≈50 000 single-nucleotide polymorphisms (SNPs) to identify RHTN in hypertensive participants coronary artery disease (CAD) from INVEST-GENES (the INnternational VErapamil-SR Trandolapril...